Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, February 25, 2026
Cellipont Bioservices announced a strategic collaboration with Soter Bio which will support integrated manufacturing pathways for complex cell therapy programs requiring coordinated biomolecule and cellular processing.
read more
Cellipont Bioservices, a cell therapy Contract Development and Manufacturing Organization (CDMO), and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies to treat a broad range of hematological and ...
read more
Tuesday, December 10, 2024
Cellipont Bioservices and Xiogenix have announced a strategic partnership that enables Cellipont Bioservices to offer its clients access to the state-of-the-art Ares™ X20 fill and finish system, significantly enhancing the precision and efficiency of...
read more
Thursday, December 04, 2025
Cellipont Bioservices announced the completion of its ballroom-style cleanroom, featuring a state-of-the-art 50-liter single-use bioreactor. This facility expansion marks a major milestone in Cellipont's continued investment to meet the growing ...
read more
Cellipont Bioservices announced the grand opening of its purpose-built 76,000 sq. ft. manufacturing facility in The Woodlands, TX. This facility includes 7 clean rooms, QC labs, temperature-controlled storage, segregated shipping bays, warehouse, and...
read more
Wednesday, April 22, 2020
Cellphire announced the BARDA has exercised its third contract option valued at $33.3 million to support Cellphire's next generation platelet-based hemostatic product, Thrombosomes.
read more
CellPoint, a cell therapy company developing CAR-T therapeutics for use at the point-of-care, announces an agreement with Lonza's Personalized Medicine Business Unit to employ Lonza's Cocoon® Platform for clinical manufacturing of CellPoint's CAR-T ...
read more
Wednesday, November 08, 2017
CellSight announced a collaboration with Boehringer Ingelheim to evaluate CellSight's PET imaging tracer, VisAcT, for future use in the development and monitoring of immune-oncological therapies.
read more
Celltrion received CRLs from the FDA regarding the BLA for CT-P10, a proposed biosimilar to Rituxan and CT-P6, a proposed biosimilar to Herceptin.
read more
Wednesday, September 27, 2017
Oracle announced Celltrion has selected Oracle Health Sciences Argus and Oracle Health Sciences Empirica Signal to streamline its pharmacovigilance case management and patient safety initiatives.
read more
Cellular Origins announced an international collaboration with Thermo Fisher Scientific that will combine Thermo Fisher’s cell culture and processing technology and Cellular Origins’ CGT robotic manufacturing platform, Constellation, to deliver full,...
read more
Friday, November 03, 2017
Celonic and Glycotope announced the completion of Celonic’s acquisition of Glycotope’s bio-manufacturing facility in Heidelberg, Germany.
read more
Tuesday, October 07, 2025
CELONIC GROUP and the Carbogen Amcis Group announced a strategic partnership to offer a fully integrated Antibody-Drug Conjugate (ADC) development and manufacturing solution. The alliance combines Celonic’s advanced biologics capabilities with ...
read more
Wednesday, February 19, 2025
Celonic Group announced the signing of a multi-year commercial manufacturing agreement with LINDIS Biotech for the production of catumaxomab for commercial supply.
read more
Celonic announced a long-term lease agreement for a new production site and office space spanning 91,500 square feet in the WST-222 building at the Novartis-operated Life Science Park Rheintal.
read more